CeriBell (NASDAQ:CBLL) Given Buy Rating at BTIG Research

CeriBell (NASDAQ:CBLL)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a report issued on Friday, Benzinga reports. They presently have a $30.00 price objective on the stock. BTIG Research’s price target suggests a potential upside of 28.04% from the stock’s current price.

Several other brokerages have also commented on CBLL. Raymond James Financial restated a “strong-buy” rating and set a $29.00 price target on shares of CeriBell in a research note on Thursday, September 3rd. Canaccord Genuity Group lifted their price target on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings downgraded shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 28th. Finally, Barclays raised shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.40.

CeriBell Stock Down 4.0%

Shares of CBLL opened at $23.43 on Friday. CeriBell has a fifty-two week low of $10.85 and a fifty-two week high of $25.33. The company’s fifty day moving average is $21.03 and its two-hundred day moving average is $19.61. The firm has a market cap of $899.24 million, a PE ratio of -13.31 and a beta of 0.95. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The firm had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. Analysts forecast that CeriBell will post -1.96 earnings per share for the current year.

Insider Activity

In other CeriBell news, CFO Scott Blumberg sold 33,512 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $25.03, for a total value of $838,805.36. Following the completion of the transaction, the chief financial officer owned 148,121 shares in the company, valued at $3,707,468.63. This represents a 18.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP David Foehr sold 9,255 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $24.25, for a total transaction of $224,433.75. Following the completion of the sale, the vice president directly owned 34,144 shares of the company’s stock, valued at $827,992. This trade represents a 21.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 391,901 shares of company stock worth $8,542,455 in the last ninety days. 17.70% of the stock is currently owned by company insiders.

Institutional Trading of CeriBell

A number of hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its holdings in CeriBell by 6,424.8% in the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after purchasing an additional 374,179 shares during the last quarter. Rhumbline Advisers raised its position in shares of CeriBell by 109.9% in the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after purchasing an additional 17,177 shares in the last quarter. New York State Common Retirement Fund boosted its stake in shares of CeriBell by 148.6% during the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after buying an additional 5,200 shares during the last quarter. Quantbot Technologies LP grew its position in shares of CeriBell by 70.3% during the second quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock worth $290,000 after buying an additional 6,401 shares in the last quarter. Finally, Invesco Ltd. bought a new stake in shares of CeriBell in the second quarter worth $197,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.